Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	B-cell_type
responded	O
to	O
stimulation	O
of	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
with	O
up-regulation	O
of	O
the	O
transcript	O
for	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
(	O
HB-EGF	B-protein
)	O
,	O
a	O
potent	B-protein
mitogen	I-protein
for	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

This	O
function	O
of	O
PAF	B-protein
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	B-protein
-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	B-protein
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B-protein
surface	I-protein
PAF	I-protein
receptors	I-protein
,	O
as	O
two	O
PAF	B-protein
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B-protein
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
markedly	O
reduced	O
PAF	B-protein
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Communication	NULL
Platelet-activating	NULL
Factor	NULL
Stimulates	NULL
Transcription	NULL
of	NULL
the	NULL
Heparin-binding	NULL
Epidermal	NULL
Growth	NULL
Factor-like	NULL
Growth	NULL
Factor	NULL
in	NULL
Monocytes	NULL
CORRELATION	NULL
WITH	NULL
AN	NULL
INCREASED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
December	NULL
16	NULL
,	NULL
1994	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
January	NULL
25	NULL
,	NULL
1995	NULL
)	NULL
Zhixing	NULL
Pan	NULL
,	NULL
Vladimir	NULL
V.	NULL
Kravchenko	NULL
,	NULL
and	NULL
Richard	NULL
D.	NULL
Yet	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
California	NULL
92037	NULL
Human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
responded	NULL
to	NULL
stimulation	NULL
of	NULL
platelet-activating	NULL
factor	NULL
(	NULL
PAF	NULL
)	NULL
with	NULL
up-regulation	NULL
of	NULL
the	NULL
transcript	NULL
for	NULL
heparin-binding	NULL
epidermal	NULL
growth	NULL
factor-like	NULL
growth	NULL
factor	NULL
(	NULL
HB-EGF	NULL
)	NULL
,	NULL
a	NULL
potent	NULL
mitogen	NULL
for	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

This	NULL
function	NULL
of	NULL
PAF	NULL
was	NULL
observed	NULL
at	NULL
nanomolar	NULL
concentrations	NULL
of	NULL
the	NULL
ligand	NULL
,	NULL
starting	NULL
at	NULL
30	NULL
min	NULL
after	NULL
stimulation	NULL
.	NULL

The	NULL
PAF-induced	NULL
up-regulation	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
was	NULL
accompanied	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
These	NULL
functions	NULL
of	NULL
PAF	NULL
appeared	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
the	NULL
cell	NULL
surface	NULL
PAF	NULL
receptors	NULL
,	NULL
as	NULL
two	NULL
PAF	NULL
receptor	NULL
antagonists	NULL
,	NULL
WEB	NULL
2086	NULL
and	NULL
L-659,989	NULL
,	NULL
blocked	NULL
both	NULL
the	NULL
up-regulation	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
and	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
induced	NULL
by	NULL
PAF	NULL
.	NULL

The	NULL
antagonists	NULL
,	NULL
however	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
phorbol	NULL
ester-induced	NULL
up-regulation	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
and	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

Pretreatment	NULL
of	NULL
monocytes	NULL
with	NULL
pertussis	NULL
toxin	NULL
inhibited	NULL
these	NULL
functions	NULL
of	NULL
PAF	NULL
,	NULL
whereas	NULL
cholera	NULL
toxin	NULL
had	NULL
no	NULL
inhibitory	NULL
effect	NULL
.	NULL

Pyrrolidine	NULL
di-thiocarbamate	NULL
,	NULL
an	NULL
inhibitor	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
markedly	NULL
reduced	NULL
PAF-stimulated	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
up-regulation	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
a	NULL
potential	NULL
role	NULL
of	NULL
PAF	NULL
in	NULL
HB-EGF	NULL
expression	NULL
and	NULL
provide	NULL
evidence	NULL
that	NULL
this	NULL
stimulation	NULL
may	NULL
occur	NULL
through	NULL
increased	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

Proliferation	NULL
of	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
SMC	NULL
)	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
atherosclerosis	NULL
into	NULL
its	NULL
advanced	NULL
stage	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
,	NULL
including	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
,	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
,	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
American	NULL
Heart	NULL
Association	NULL
Grant-in-aid	NULL
92-978	NULL
and	NULL
by	NULL
United	NULL
States	NULL
Public	NULL
Health	NULL
Service	NULL
Grant	NULL
GM46572	NULL
.	NULL

This	NULL
is	NULL
Publication	NULL
9054-IMM	NULL
from	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

?	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
and	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Immunology	NULL
,	NULL
IMM-12	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
92037	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
619-554-8588	NULL
;	NULL
Fax	NULL
:	NULL
619-554-8483	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
SMC	NULL
,	NULL
smooth	NULL
muscle	NULL
cells	NULL
;	NULL
PAF	NULL
,	NULL
platelet-activating	NULL
factor	NULL
;	NULL
HB-EGF	NULL
,	NULL
heparin-binding	NULL
epidermal	NULL
growth	NULL
factor-like	NULL
growth	NULL
factor	NULL
;	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor	NULL
xB	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
PDTC	NULL
,	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
;	NULL
TNFa	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
;	NULL
PTK	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
PTX	NULL
,	NULL
pertussis	NULL
toxin	NULL
;	NULL
CTX	NULL
,	NULL
cholera	NULL
toxin	NULL
.	NULL

THE	NULL
JourNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

270	NULL
,	NULL
No	NULL
.	NULL

14	NULL
,	NULL
Issue	NULL
of	NULL
April	NULL
7	NULL
,	NULL
pp	NULL
.	NULL

7787-7790	NULL
,	NULL
1995	NULL
©1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc	NULL
.	NULL

Printed	NULL
in	NULL
U.S.A.	NULL
transforming	NULL
growth	NULL
factor-B	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
(	NULL
TNFa	NULL
)	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
stimulate	NULL
SMC	NULL
proliferation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

These	NULL
factors	NULL
may	NULL
be	NULL
produced	NULL
at	NULL
the	NULL
site	NULL
of	NULL
lesion	NULL
by	NULL
endothelial	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
monocytes	NULL
,	NULL
which	NULL
are	NULL
attracted	NULL
to	NULL
the	NULL
subendo-thelial	NULL
region	NULL
by	NULL
locally	NULL
produced	NULL
chemoattractants	NULL
such	NULL
as	NULL
monocyte	NULL
chemotactic	NULL
protein-1	NULL
,	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
and	NULL
transforming	NULL
growth	NULL
factor-8	NULL
(	NULL
1	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
monocytic	NULL
cells	NULL
produce	NULL
a	NULL
protein	NULL
that	NULL
binds	NULL
the	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
receptor	NULL
with	NULL
10-fold	NULL
higher	NULL
affinity	NULL
than	NULL
EGF	NULL
itself	NULL
(	NULL
3	NULL
)	NULL
.	NULL

This	NULL
molecule	NULL
,	NULL
termed	NULL
heparin-binding	NULL
EGF-like	NULL
growth	NULL
factor	NULL
(	NULL
HB-EGEF	NULL
)	NULL
,	NULL
is	NULL
also	NULL
produced	NULL
by	NULL
SMC	NULL
and	NULL
acts	NULL
as	NULL
a	NULL
potent	NULL
mitogen	NULL
for	NULL
SMC	NULL
by	NULL
an	NULL
autocrine	NULL
mechanism	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

HB-EGF	NULL
is	NULL
a	NULL
22-kDa	NULL
single-chain	NULL
polypeptide	NULL
with	NULL
an	NULL
EGF-like	NULL
domain	NULL
and	NULL
a	NULL
heparin-binding	NULL
domain	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
as	NULL
well	NULL
as	NULL
the	NULL
gene	NULL
for	NULL
HB-EGF	NULL
have	NULL
been	NULL
cloned	NULL
(	NULL
3	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
synthesis	NULL
of	NULL
HB-EGF	NULL
is	NULL
up-regulated	NULL
by	NULL
a	NULL
number	NULL
of	NULL
factors	NULL
including	NULL
lysophos-phatidylcholine	NULL
,	NULL
phorbol	NULL
ester	NULL
,	NULL
angiotensin	NULL
II	NULL
,	NULL
and	NULL
thrombin	NULL
(	NULL
6	NULL
,	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
mechanisms	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
HB-EGF	NULL
expression	NULL
,	NULL
however	NULL
,	NULL
are	NULL
not	NULL
fully	NULL
understood	NULL
.	NULL

PAF	NULL
,	NULL
a	NULL
biologically	NULL
active	NULL
phospholipid	NULL
(	NULL
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine	NULL
)	NULL
,	NULL
is	NULL
a	NULL
substance	NULL
released	NULL
by	NULL
many	NULL
cells	NULL
including	NULL
monocyte/macrophages	NULL
,	NULL
endothelial	NULL
cells	NULL
,	NULL
poly-morphonuclear	NULL
cells	NULL
,	NULL
and	NULL
platelets	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

10	NULL
and	NULL
11	NULL
)	NULL
.	NULL

PAF	NULL
exerts	NULL
its	NULL
effects	NULL
through	NULL
binding	NULL
to	NULL
specific	NULL
receptors	NULL
in	NULL
target	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Recent	NULL
cloning	NULL
of	NULL
the	NULL
PAF	NULL
receptor	NULL
indicates	NULL
that	NULL
it	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
G	NULL
protein-coupled	NULL
receptor	NULL
superfamily	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

PAF	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
atherogenesis	NULL
and	NULL
atherosclerosis	NULL
,	NULL
and	NULL
clinical	NULL
studies	NULL
indicated	NULL
higher	NULL
levels	NULL
of	NULL
PAF	NULL
in	NULL
coronary	NULL
artery	NULL
samples	NULL
from	NULL
patients	NULL
with	NULL
severe	NULL
atherosclerosis	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

A	NULL
major	NULL
part	NULL
of	NULL
the	NULL
action	NULL
of	NULL
PAF	NULL
during	NULL
atherogenesis	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
a	NULL
juxtacrine	NULL
intercellular	NULL
signaling	NULL
mechanism	NULL
in	NULL
which	NULL
PAF	NULL
synthesized	NULL
by	NULL
endothelial	NULL
cells	NULL
is	NULL
attached	NULL
to	NULL
the	NULL
surface	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
which	NULL
could	NULL
form	NULL
a	NULL
close	NULL
interaction	NULL
with	NULL
leukocytes	NULL
through	NULL
P-selectin	NULL
(	NULL
20	NULL
)	NULL
.	NULL

This	NULL
interaction	NULL
may	NULL
be	NULL
important	NULL
for	NULL
the	NULL
subsequent	NULL
monocyte/macrophage	NULL
activation	NULL
,	NULL
secretion	NULL
of	NULL
proliferative	NULL
agents	NULL
,	NULL
migration	NULL
between	NULL
the	NULL
endothelium	NULL
,	NULL
and	NULL
eventually	NULL
accumulation	NULL
of	NULL
lipid	NULL
within	NULL
the	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
function	NULL
of	NULL
PAF	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
expression	NULL
of	NULL
growth	NULL
factors	NULL
in	NULL
monocytes	NULL
and	NULL
attempted	NULL
to	NULL
establish	NULL
the	NULL
relationship	NULL
between	NULL
the	NULL
expression	NULL
of	NULL
HB-EGF	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
specific	NULL
transcription	NULL
factors	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
PAF	NULL
is	NULL
a	NULL
strong	NULL
inducer	NULL
for	NULL
HB-EGF	NULL
expression	NULL
in	NULL
monocytes	NULL
,	NULL
and	NULL
this	NULL
function	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
enhanced	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
suggesting	NULL
potential	NULL
involvement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
PAF-induced	NULL
gene	NULL
regulation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Preparation	NULL
of	NULL
Monocytes	NULL
from	NULL
Peripheral	NULL
Blood-Heparinized	NULL
human	NULL
peripheral	NULL
blood	NULL
from	NULL
health	NULL
donors	NULL
was	NULL
fractionated	NULL
on	NULL
Percoll	NULL
density	NULL
gradients	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
monocytes	NULL
were	NULL
isolated	NULL
using	NULL
gelatin/plasma-coated	NULL
flasks	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
monocytes	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
as	NULL
determined	NULL
by	NULL
staining	NULL
with	NULL
the	NULL
anti-CD14	NULL
monoclonal	NULL
antibody	NULL
MY4	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
greater	NULL
than	NULL
98	NULL
%	NULL
as	NULL
measured	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

Monocytes	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Irvine	NULL
Scientific	NULL
)	NULL
with	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

For	NULL
isolation	NULL
of	NULL
total	NULL
RNA	NULL
and	NULL
extraction	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
the	NULL
culture	NULL
medium	NULL
in	NULL
sterile	NULL
1.5-ml	NULL
polypropylene	NULL
microcentrifuge	NULL
tubes	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
without	NULL
serum	NULL
for	NULL
12	NULL
h	NULL
before	NULL
stimulation	NULL
with	NULL
ligands	NULL
.	NULL

RNA	NULL
Extraction	NULL
and	NULL
Northern	NULL
Blotting-Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
monocytes	NULL
by	NULL
a	NULL
modified	NULL
guanidinium/acidic	NULL
phenol	NULL
method	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
ligands	NULL
as	NULL
well	NULL
7787	NULL
7788	NULL
as	NULL
the	NULL
PAF	NULL
antagonists	NULL
WEB	NULL
2086	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Boehringer	NULL
Ingelheim	NULL
,	NULL
Ridgefield	NULL
,	NULL
CT	NULL
)	NULL
or	NULL
L-659,989	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Merck	NULL
&	NULL
Co.	NULL
)	NULL
.	NULL

About	NULL
20	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
in	NULL
agarose	NULL
gels	NULL
containing	NULL
6	NULL
%	NULL
formaldehyde	NULL
and	NULL
transferred	NULL
to	NULL
the	NULL
Hybond-N	NULL
plus	NULL
membranes	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
by	NULL
the	NULL
diffusion	NULL
method	NULL
.	NULL

A	NULL
616-base	NULL
pair	NULL
HindIII-Xbal	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
HB-EGF	NULL
cDNA	NULL
was	NULL
synthesized	NULL
from	NULL
U937	NULL
total	NULL
RNA	NULL
by	NULL
reverse	NULL
transcriptase	NULL
polymerase	NULL
chain	NULL
reac-tion	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
primers	NULL
are	NULL
:	NULL
5-ATG	NULL
AAG	NULL
CTT	NULL
CTG	NULL
CCG	NULL
TCG	NULL
GTG-3	NULL
and	NULL
5-TGT	NULL
CTA	NULL
GAT	NULL
GCC	NULL
CAA	NULL
CTT	NULL
CAC	NULL
TTT	NULL
CTC-3	NULL
.	NULL

The	NULL
polymerase	NULL
chain	NULL
reaction-amplified	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
the	NULL
restriction	NULL
enzymes	NULL
HindIII	NULL
and	NULL
Xbal	NULL
,	NULL
and	NULL
subcloned	NULL
into	NULL
the	NULL
same	NULL
sites	NULL
in	NULL
pBluescript	NULL
SK	NULL
(	NULL
+	NULL
)	NULL
plasmid	NULL
vector	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

For	NULL
Northern	NULL
hybridization	NULL
,	NULL
the	NULL
fragment	NULL
was	NULL
labeled	NULL
with	NULL
[	NULL
*P	NULL
]	NULL
dATP	NULL
to	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
>	NULL
5	NULL
x	NULL
10°	NULL
cpm/ug	NULL
of	NULL
DNA	NULL
by	NULL
the	NULL
random	NULL
priming	NULL
method	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
prehybridized	NULL
in	NULL
6	NULL
x	NULL
SSC	NULL
,	NULL
5	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
65	NULL
°C	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
hybridized	NULL
with	NULL
the	NULL
*°P-labeled	NULL
probe	NULL
(	NULL
1	NULL
x	NULL
10°	NULL
cpm/ml	NULL
)	NULL
for	NULL
16	NULL
h	NULL
at	NULL
the	NULL
same	NULL
temperature	NULL
.	NULL

Filters	NULL
were	NULL
washed	NULL
with	NULL
2	NULL
x	NULL
SSC	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
65	NULL
°C	NULL
,	NULL
followed	NULL
by	NULL
another	NULL
wash	NULL
with	NULL
0.1	NULL
x	NULL
SSC	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
exposed	NULL
to	NULL
Hyperfilm-MP	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
with	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

Relative	NULL
hybridization	NULL
was	NULL
analyzed	NULL
for	NULL
quantitation	NULL
of	NULL
actual	NULL
radioactivity	NULL
by	NULL
a	NULL
Phosphor-Imaging	NULL
System	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

The	NULL
quantity	NULL
of	NULL
samples	NULL
in	NULL
each	NULL
lane	NULL
was	NULL
standardized	NULL
against	NULL
relative	NULL
staining	NULL
of	NULL
the	NULL
18	NULL
and	NULL
28	NULL
S	NULL
RNA	NULL
after	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
Extracts-Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

Aliquots	NULL
of	NULL
monocytes	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells/sample	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
different	NULL
agents	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
text	NULL
,	NULL
after	NULL
which	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
ice-cold	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
0.4	NULL
ml	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
my	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mm	NULL
KCl	NULL
,	NULL
1	NULL
mi	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
each	NULL
of	NULL
EDTA	NULL
and	NULL
EGTA	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
.	NULL

After	NULL
10	NULL
min	NULL
,	NULL
23	NULL
ul	NULL
of	NULL
10	NULL
%	NULL
Nonidet	NULL
P-40	NULL
was	NULL
added	NULL
and	NULL
briefly	NULL
mixed	NULL
for	NULL
2	NULL
s.	NULL
Nuclei	NULL
were	NULL
separated	NULL
from	NULL
cytosol	NULL
by	NULL
centrifugation	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
s	NULL
and	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
Ll	NULL
of	NULL
buffer	NULL
B	NULL
(	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
0.4	NULL
M	NULL
NaCl	NULL
,	NULL
1	NULL
ma	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
EGTA	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
.	NULL

After	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
lysates	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
(	NULL
13,000	NULL
x	NULL
g	NULL
,	NULL
30	NULL
s	NULL
)	NULL
and	NULL
the	NULL
supernatants	NULL
containing	NULL
nuclear	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
new	NULL
vials	NULL
.	NULL

Samples	NULL
were	NULL
diluted	NULL
to	NULL
equal	NULL
concentration	NULL
in	NULL
buffer	NULL
B.	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
(	NULL
EMSA	NULL
)	NULL
-Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
2.5	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
added	NULL
to	NULL
12	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
5	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
50	NULL
mm	NULL
KCl	NULL
,	NULL
0.5	NULL
mi	NULL
dithiothreitol	NULL
,	NULL
0.4	NULL
mg/ml	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
0.1	NULL
mg/ml	NULL
sonicated	NULL
salmon	NULL
sperm	NULL
DNA	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Approximately	NULL
20-50	NULL
fmol	NULL
of	NULL
*°P-labeled	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
30,000-50,000	NULL
cpm	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
on	NULL
5	NULL
%	NULL
acrylamide	NULL
gel	NULL
,	NULL
made	NULL
with	NULL
buffers	NULL
containing	NULL
either	NULL
50	NULL
mit	NULL
Tris	NULL
borate	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
(	NULL
TBE	NULL
)	NULL
or	NULL
50	NULL
mit	NULL
Tris	NULL
,	NULL
380	NULL
mit	NULL
glycine	NULL
,	NULL
2	NULL
mit	NULL
EDTA	NULL
(	NULL
TGE	NULL
)	NULL
.	NULL

After	NULL
pre-electrophore-sis	NULL
for	NULL
2	NULL
h	NULL
at	NULL
12	NULL
V/cm	NULL
,	NULL
electrophoresis	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
the	NULL
same	NULL
voltage	NULL
for	NULL
2-2.5	NULL
h.	NULL
The	NULL
gel	NULL
contents	NULL
were	NULL
transferred	NULL
to	NULL
Whatman	NULL
DE-81	NULL
paper	NULL
,	NULL
dried	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
either	NULL
x-ray	NULL
film	NULL
or	NULL
PhosphorImager	NULL
screen	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
Stimulation	NULL
of	NULL
HB-EGF	NULL
Gene	NULL
Expression	NULL
by	NULL
PAF-Macro-phage-like	NULL
U-937	NULL
cells	NULL
produce	NULL
HB-EGF	NULL
in	NULL
response	NULL
to	NULL
treatment	NULL
with	NULL
PMA	NULL
,	NULL
which	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
an	NULL
inducer	NULL
of	NULL
the	NULL
HB-EGF	NULL
mRNA	NULL
in	NULL
SMC	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
PAF	NULL
,	NULL
generated	NULL
at	NULL
the	NULL
site	NULL
of	NULL
vascular	NULL
injury	NULL
during	NULL
atherogenesis	NULL
,	NULL
on	NULL
HB-EGF	NULL
gene	NULL
transcription	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
HB-EGF	NULL
message	NULL
was	NULL
examined	NULL
by	NULL
hybridization	NULL
of	NULL
a	NULL
-labeled	NULL
human	NULL
HB-EGF	NULL
cDNA	NULL
probe	NULL
to	NULL
total	NULL
RNA	NULL
isolate	NULL
from	NULL
human	NULL
monocytes	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

A	NULL
major	NULL
species	NULL
of	NULL
2.5	NULL
kilobases	NULL
was	NULL
found	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
TNFa	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
PAF	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
but	NULL
not	NULL
in	NULL
untreated	NULL
monocytes	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
base-line	NULL
level	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
was	NULL
very	NULL
low	NULL
,	NULL
it	NULL
increased	NULL
rapidly	NULL
after	NULL
stimulation	NULL
with	NULL
PAF	NULL
and	NULL
was	NULL
maintained	NULL
for	NULL
at	NULL
least	NULL
4	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

PAF	NULL
increased	NULL
HB-EGF	NULL
mRNA	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
with	NULL
a	NULL
maximal	NULL
response	NULL
achieved	NULL
in	NULL
approximately	NULL
10	NULL
nm	NULL
PAF	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Actinomycin	NULL
D	NULL
,	NULL
an	NULL
inhibitor	NULL
for	NULL
2	NULL
V.	NULL
V.	NULL
Kravchenko	NULL
,	NULL
Z.	NULL
Pan	NULL
,	NULL
J.	NULL
Han	NULL
,	NULL
J.-M.	NULL
Herbert	NULL
,	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Ye	NULL
,	NULL
submitted	NULL
for	NULL
publication	NULL
.	NULL

PAF	NULL
Induces	NULL
HB-EGF	NULL
Gene	NULL
Expression	NULL
A	NULL
B	NULL
C	NULL
288	NULL
>	NULL
Dose	NULL
(	NULL
nM	NULL
)	NULL
-	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
PAF	NULL
+	NULL
ActD	NULL
18	NULL
$	NULL
>	NULL
PAF	NULL
28S	NULL
>	NULL
185	NULL
>	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

PAF-induced	NULL
expression	NULL
of	NULL
HB-EGF	NULL
gene	NULL
in	NULL
monocytes	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
under	NULL
various	NULL
conditions	NULL
before	NULL
RNA	NULL
extraction	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
were	NULL
subject	NULL
to	NULL
Northern	NULL
blot	NULL
analysis	NULL
with	NULL
a	NULL
*°P-labeled	NULL
human	NULL
HB-EGF	NULL
probe	NULL
.	NULL

A	NULL
,	NULL
autoradiograph	NULL
of	NULL
Northern	NULL
blot	NULL
with	NULL
RNA	NULL
from	NULL
monocytes	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
PMA	NULL
(	NULL
100	NULL
ni	NULL
)	NULL
,	NULL
TNFa	NULL
(	NULL
40	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
PAF	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
for	NULL
60	NULL
min	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

B	NULL
,	NULL
dose-	NULL
and	NULL
time-dependent	NULL
expression	NULL
of	NULL
HB-EGF	NULL
mRNA	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
different	NULL
doses	NULL
of	NULL
PAF	NULL
for	NULL
60	NULL
min	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
after	NULL
stimulation	NULL
with	NULL
100	NULL
nM	NULL
PAF	NULL
at	NULL
the	NULL
time	NULL
points	NULL
indicated	NULL
(	NULL
Zanes	NULL
5-8	NULL
)	NULL
.	NULL

C	NULL
,	NULL
effect	NULL
of	NULL
actinomycin	NULL
D	NULL
(	NULL
ActD	NULL
)	NULL
on	NULL
HB-EGF	NULL
gene	NULL
transcription	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
100	NULL
nm	NULL
PAF	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
of	NULL
1	NULL
ug/ml	NULL
actinomycin	NULL
D	NULL
for	NULL
60	NULL
min	NULL
before	NULL
extraction	NULL
of	NULL
RNA	NULL
.	NULL

The	NULL
bottom	NULL
part	NULL
of	NULL
panel	NULL
A	NULL
is	NULL
a	NULL
photograph	NULL
of	NULL
the	NULL
same	NULL
gel	NULL
before	NULL
transfer	NULL
to	NULL
membrane	NULL
,	NULL
with	NULL
the	NULL
relative	NULL
molecular	NULL
sizes	NULL
marked	NULL
by	NULL
the	NULL
18	NULL
and	NULL
28	NULL
S	NULL
RNA	NULL
species	NULL
.	NULL

Sample	NULL
loading	NULL
was	NULL
similarly	NULL
controlled	NULL
for	NULL
Northern	NULL
blots	NULL
shown	NULL
in	NULL
other	NULL
figure	NULL
panels	NULL
.	NULL

RNA	NULL
synthesis	NULL
,	NULL
blocked	NULL
PAF-stimulated	NULL
increase	NULL
of	NULL
the	NULL
HB-EGF	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
stimulation	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
contributes	NULL
to	NULL
PAF-induced	NULL
up-regulation	NULL
of	NULL
the	NULL
HB-EGF	NULL
message	NULL
.	NULL

Effect	NULL
of	NULL
PAF	NULL
Receptor	NULL
Antagonists	NULL
and	NULL
a	NULL
Bacterial	NULL
Toxin	NULL
on	NULL
HB-EGF	NULL
Gene	NULL
Expression-To	NULL
investigate	NULL
whether	NULL
PAF	NULL
's	NULL
effect	NULL
on	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
specific	NULL
cell	NULL
surface	NULL
PAF	NULL
receptor	NULL
,	NULL
we	NULL
employed	NULL
the	NULL
PAF	NULL
receptor	NULL
antagonists	NULL
,	NULL
L-659,989	NULL
and	NULL
WEB	NULL
2086	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
pretreated	NULL
with	NULL
L-659,989	NULL
(	NULL
1	NULL
um	NULL
)	NULL
or	NULL
WEB	NULL
2086	NULL
(	NULL
10	NULL
um	NULL
)	NULL
prior	NULL
to	NULL
stimulation	NULL
by	NULL
PAF	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
both	NULL
antagonists	NULL
markedly	NULL
inhibited	NULL
PAF-induced	NULL
HB-EGF	NULL
expression	NULL
in	NULL
monocytes	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neither	NULL
antagonist	NULL
had	NULL
an	NULL
effect	NULL
on	NULL
PMA-induced	NULL
expression	NULL
of	NULL
HB-EGF	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
the	NULL
antagonists	NULL
alone	NULL
did	NULL
not	NULL
induce	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

PAF	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
a	NULL
receptor	NULL
that	NULL
functionally	NULL
couples	NULL
to	NULL
G	NULL
proteins	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
,	NULL
and	NULL
recent	NULL
cloning	NULL
of	NULL
the	NULL
PAF	NULL
receptor	NULL
confirmed	NULL
that	NULL
it	NULL
possesses	NULL
a	NULL
typical	NULL
structure	NULL
for	NULL
G	NULL
protein-coupled	NULL
receptors	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
whether	NULL
PAF-induced	NULL
HB-EGF	NULL
mRNA	NULL
synthesis	NULL
is	NULL
subject	NULL
to	NULL
inhibition	NULL
by	NULL
bacterial	NULL
toxins	NULL
that	NULL
ADP-ribosylate	NULL
'	NULL
the	NULL
a-subunits	NULL
of	NULL
certain	NULL
(	NULL
G	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
pertussis	NULL
toxin	NULL
(	NULL
PTX	NULL
)	NULL
significantly	NULL
reduced	NULL
PAF-induced	NULL
HB-EGF	NULL
message	NULL
up-regulation	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
,	NULL
while	NULL
cholera	NULL
toxin	NULL
(	NULL
CTX	NULL
)	NULL
has	NULL
no	NULL
such	NULL
inhibitory	NULL
effect	NULL
in	NULL
monocytes	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Neither	NULL
of	NULL
the	NULL
two	NULL
toxins	NULL
inhibited	NULL
PMA-induced	NULL
expression	NULL
of	NULL
the	NULL
HB-EGF	NULL
gene	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
a	NULL
preliminary	NULL
study	NULL
of	NULL
the	NULL
potential	NULL
mechanisms	NULL
for	NULL
PAF-stimulated	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
requirement	NULL
for	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
PTK	NULL
)	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
activity	NULL
in	NULL
PAF-induced	NULL
HB-EGF	NULL
expression	NULL
.	NULL

Monocytes	NULL
were	NULL
treated	NULL
with	NULL
herbimycin	NULL
A	NULL
and	NULL
staurosporine	NULL
,	NULL
inhibitors	NULL
for	NULL
PTK	NULL
and	NULL
PKC	NULL
,	NULL
respectively	NULL
.	NULL

Herbimycin	NULL
A	NULL
treatment	NULL
(	NULL
1	NULL
um	NULL
,	NULL
40	NULL
min	NULL
)	NULL
completely	NULL
inhibited	NULL
PAF-induced	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
staurosporine	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
functions	NULL
of	NULL
protein	NULL
kinases	NULL
in	NULL
this	NULL
process	NULL
.	NULL

PAF-induced	NULL
Gene	NULL
Expression	NULL
of	NULL
HB-EGF	NULL
Is	NULL
Associated	NULL
with	NULL
a	NULL
kB	NULL
DNA	NULL
Binding	NULL
Activity-One	NULL
of	NULL
the	NULL
mediators	NULL
for	NULL
immediate-early	NULL
gene	NULL
expression	NULL
is	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
PAF	NULL
Induces	NULL
HB-EGF	NULL
Gene	NULL
Expression	NULL
&	NULL
€	NULL
*	NULL
+	NULL
<	NULL
=	NULL
<	NULL
a	NULL
a	NULL
PMA	NULL
+	NULL
CTX	NULL
-	NULL
PAF	NULL
+	NULL
STSP	NULL
€	NULL
3	NULL
”	NULL
g	NULL
“	NULL
.	NULL

$	NULL
&	NULL
fe	NULL
28S	NULL
>	NULL
188	NULL
>	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Effect	NULL
of	NULL
PAF	NULL
antagonists	NULL
,	NULL
bacterial	NULL
toxins	NULL
,	NULL
and	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
on	NULL
PAF-induced	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
.	NULL

Northern	NULL
blot	NULL
with	NULL
total	NULL
RNA	NULL
(	NULL
20	NULL
ug/lane	NULL
)	NULL
isolated	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
as	NULL
indicated	NULL
below	NULL
is	NULL
shown	NULL
.	NULL

A	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
L-659,989	NULL
(	NULL
10	NULL
un	NULL
;	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
WEB	NULL
2086	NULL
(	NULL
10	NULL
um	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
before	NULL
stimulation	NULL
for	NULL
60	NULL
min	NULL
with	NULL
PAF	NULL
(	NULL
100	NULL
nm	NULL
;	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
100	NULL
ni	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

B	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PTX	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
or	NULL
CTX	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
stimulation	NULL
for	NULL
60	NULL
min	NULL
with	NULL
either	NULL
PAF	NULL
(	NULL
100	NULL
ni	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
100	NULL
ni	NULL
)	NULL
.	NULL

Lanes	NULL
1-3	NULL
,	NULL
without	NULL
toxin	NULL
treatment	NULL
.	NULL

C	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
40	NULL
min	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
,	NULL
1	NULL
um	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
staurosporine	NULL
(	NULL
STSP	NULL
,	NULL
200	NULL
nM	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
PAF	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
stimulation	NULL
for	NULL
60	NULL
min	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
no	NULL
PAF	NULL
or	NULL
inhibitor	NULL
treatment	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
PAF	NULL
only	NULL
.	NULL

couples	NULL
extracellular	NULL
signals	NULL
to	NULL
gene-activating	NULL
events	NULL
.	NULL

The	NULL
pro-totypic	NULL
NF-kB	NULL
is	NULL
a	NULL
heterodimer	NULL
consisting	NULL
of	NULL
p50	NULL
and	NULL
p65	NULL
sub-units	NULL
and	NULL
exists	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
due	NULL
to	NULL
association	NULL
with	NULL
the	NULL
specific	NULL
inhibitor	NULL
protein	NULL
IB	NULL
.	NULL

Phosphorylation	NULL
of	NULL
IxB	NULL
by	NULL
candidate	NULL
kinases	NULL
leads	NULL
to	NULL
the	NULL
release	NULL
and	NULL
subsequent	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
then	NULL
binds	NULL
a	NULL
decam-eric	NULL
DNA	NULL
sequence	NULL
originally	NULL
identified	NULL
in	NULL
the	NULL
x	NULL
light	NULL
chain	NULL
enhancer	NULL
of	NULL
immunoglobulin	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
potential	NULL
involvement	NULL
of	NULL
PTK	NULL
and	NULL
PKC	NULL
in	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
the	NULL
possible	NULL
induction	NULL
of	NULL
kB	NULL
binding	NULL
activity	NULL
by	NULL
PAF	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
HB-EGF	NULL
gene	NULL
in	NULL
monocytes	NULL
.	NULL

Our	NULL
results	NULL
demonstrated	NULL
that	NULL
PAF	NULL
stimulated	NULL
a	NULL
rapid	NULL
rise	NULL
in	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
observed	NULL
within	NULL
20	NULL
min	NULL
,	NULL
peaked	NULL
at	NULL
1	NULL
h	NULL
,	NULL
and	NULL
returned	NULL
to	NULL
base	NULL
line	NULL
after	NULL
5	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lanes	NULL
10-14	NULL
)	NULL
.	NULL

PAF	NULL
induced	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
proportional	NULL
to	NULL
the	NULL
concentrations	NULL
required	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
HB-EGF	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lanes	NULL
5-9	NULL
)	NULL
.	NULL

Maximal	NULL
response	NULL
was	NULL
obtained	NULL
at	NULL
10	NULL
nm	NULL
PAF	NULL
,	NULL
and	NULL
a	NULL
higher	NULL
concentration	NULL
of	NULL
PAF	NULL
(	NULL
100	NULL
nmi	NULL
)	NULL
did	NULL
not	NULL
produce	NULL
an	NULL
additional	NULL
increase	NULL
in	NULL
the	NULL
«	NULL
kB	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
PAF	NULL
receptor	NULL
antagonists	NULL
L-659,989	NULL
and	NULL
WEB	NULL
2086	NULL
both	NULL
blocked	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
stimulated	NULL
by	NULL
PAF	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
but	NULL
not	NULL
that	NULL
stimulated	NULL
by	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

When	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
bacterial	NULL
toxins	NULL
as	NULL
described	NULL
above	NULL
,	NULL
PTX	NULL
blocked	NULL
PAF-induced	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
but	NULL
not	NULL
that	NULL
induced	NULL
by	NULL
PMA	NULL
,	NULL
whereas	NULL
CTX	NULL
had	NULL
no	NULL
inhibitory	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
PAF	NULL
could	NULL
induce	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
monocytes	NULL
through	NULL
a	NULL
receptor-mediated	NULL
and	NULL
G	NULL
protein-coupled	NULL
pathway	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
herbimycin	NULL
A	NULL
and	NULL
staurosporine	NULL
on	NULL
PAF-induced	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

Both	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
,	NULL
at	NULL
concentrations	NULL
that	NULL
blocked	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
,	NULL
produced	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
the	NULL
kB	NULL
binding	NULL
activity	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
suggested	NULL
the	NULL
possible	NULL
involvement	NULL
of	NULL
PTK	NULL
and	NULL
PKC	NULL
in	NULL
PAF-stimulated	NULL
«	NULL
kB	NULL
binding	NULL
activity	NULL
in	NULL
monocytes	NULL
.	NULL

Results	NULL
presented	NULL
above	NULL
demonstrated	NULL
parallel	NULL
stimulation	NULL
of	NULL
the	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
and	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
upon	NULL
PAF	NULL
stimulation	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
could	NULL
be	NULL
the	NULL
result	NULL
of	NULL
PAF-induced	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
(	NULL
PDTC	NULL
)	NULL
on	NULL
both	NULL
the	NULL
gene	NULL
expression	NULL
and	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
PAF-stimulated	NULL
monocytes	NULL
.	NULL

PDTC	NULL
is	NULL
an	NULL
antioxidant	NULL
that	NULL
selectively	NULL
blocks	NULL
the	NULL
dissociation	NULL
of	NULL
IxB	NULL
from	NULL
the	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-kB	NULL
(	NULL
27	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
PDTC	NULL
treatment	NULL
of	NULL
monocytes	NULL
significantly	NULL
inhibited	NULL
the	NULL
«	NULL
kB	NULL
binding	NULL
activity	NULL
induced	NULL
by	NULL
PAF	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

The	NULL
same	NULL
treatment	NULL
also	NULL
nearly	NULL
completely	NULL
blocked	NULL
PAF	NULL
7789	NULL
A	NULL
B	NULL
-	NULL
sL	NULL
ge	NULL
B	NULL
PAF	NULL
dose	NULL
(	NULL
nM	NULL
)	NULL
PAF	NULL
time	NULL
(	NULL
min	NULL
)	NULL
§0	NULL
11	NULL
%	NULL
)	NULL
rf	NULL
$	NULL
E	NULL
-	NULL
<	NULL
%	NULL
.	NULL

ss	NULL
as	NULL
$	NULL
%	NULL
$	NULL
j	NULL
&	NULL
§5.e	NULL
8.as	NULL
ss	NULL
s	NULL
&	NULL
f	NULL
f	NULL
&	NULL
&	NULL
&	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

PAF-induced	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
monocytes	NULL
.	NULL

Shown	NULL
are	NULL
autoradiographs	NULL
of	NULL
EMSA	NULL
results	NULL
.	NULL

A	NULL
,	NULL
monocytes	NULL
were	NULL
stimulated	NULL
with	NULL
PAF	NULL
(	NULL
0.01-100	NULL
nm	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
,	NULL
TNFa	NULL
(	NULL
40	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
(	NULL
0.1	NULL
ug/ml	NULL
)	NULL
for	NULL
40	NULL
min	NULL
or	NULL
as	NULL
indicated	NULL
before	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

A	NULL
*°P-labeled	NULL
21-mer	NULL
,	NULL
containing	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
site	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
,	NULL
was	NULL
used	NULL
for	NULL
EMSA	NULL
.	NULL

B	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
L-659,989	NULL
(	NULL
10	NULL
unt	NULL
)	NULL
and	NULL
WEB	NULL
2086	NULL
(	NULL
10	NULL
un	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
100	NULL
nm	NULL
PAF	NULL
for	NULL
40	NULL
min	NULL
.	NULL

PDTC	NULL
(	NULL
uM	NULL
)	NULL
PDTC	NULL
(	NULL
uM	NULL
)	NULL
o	NULL
8	NULL
o	NULL
m	NULL
a	NULL
--	NULL
28S	NULL
>	NULL
188	NULL
>	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Inhibition	NULL
of	NULL
PAF-induced	NULL
«	NULL
xB	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
by	NULL
PDTC	NULL
.	NULL

A	NULL
,	NULL
PDTC	NULL
inhibits	NULL
PAF-induced	NULL
xB	NULL
binding	NULL
activity	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
monocytes	NULL
preincubated	NULL
for	NULL
40	NULL
min	NULL
with	NULL
PDTC	NULL
at	NULL
the	NULL
indicated	NULL
concentra-tions	NULL
,	NULL
followed	NULL
by	NULL
PAF	NULL
(	NULL
100	NULL
ni	NULL
)	NULL
stimulation	NULL
for	NULL
60	NULL
min	NULL
.	NULL

The	NULL
autoradiograph	NULL
of	NULL
EMSA	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

B	NULL
,	NULL
PDTC	NULL
inhibits	NULL
PAF-induced	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
.	NULL

Cells	NULL
pretreated	NULL
with	NULL
PDTC	NULL
,	NULL
as	NULL
indicated	NULL
above	NULL
,	NULL
were	NULL
stimulated	NULL
with	NULL
PAF	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
for	NULL
60	NULL
min	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
for	NULL
Northern	NULL
blot	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
for	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
autoradiograph	NULL
of	NULL
the	NULL
Northern	NULL
blot	NULL
is	NULL
shown	NULL
.	NULL

induced	NULL
expression	NULL
of	NULL
the	NULL
HB-EGF	NULL
transcript	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
with	NULL
kB	NULL
binding	NULL
activity	NULL
participate	NULL
in	NULL
PAF-stimulated	NULL
HB-EGF	NULL
gene	NULL
transcription	NULL
.	NULL

HB-EGF	NULL
was	NULL
originally	NULL
purified	NULL
from	NULL
conditioned	NULL
medium	NULL
of	NULL
cultured	NULL
human	NULL
mononuclear	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
and	NULL
the	NULL
monocytic	NULL
U-937	NULL
cell	NULL
line	NULL
(	NULL
3	NULL
)	NULL
.	NULL

It	NULL
was	NULL
subsequently	NULL
found	NULL
that	NULL
HB-EGF	NULL
could	NULL
be	NULL
transcribed	NULL
in	NULL
vascular	NULL
endothelial	NULL
cells	NULL
(	NULL
29	NULL
)	NULL
and	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
6	NULL
)	NULL
;	NULL
both	NULL
are	NULL
associated	NULL
with	NULL
atherogenesis	NULL
.	NULL

HB-EGF	NULL
is	NULL
a	NULL
more	NULL
potent	NULL
mitogen	NULL
than	NULL
EGF	NULL
for	NULL
smooth	NULL
muscle	NULL
cell	NULL
proliferation	NULL
(	NULL
3	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
HB-EGF	NULL
in	NULL
these	NULL
cells	NULL
is	NULL
highly	NULL
regulated	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
factors	NULL
that	NULL
participate	NULL
in	NULL
atherogenesis	NULL
,	NULL
such	NULL
as	NULL
TNFa	NULL
and	NULL
thrombin	NULL
,	NULL
also	NULL
up-regulate	NULL
the	NULL
expression	NULL
of	NULL
HB-EGF	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
these	NULL
findings	NULL
,	NULL
the	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
HB-EGF	NULL
gene	NULL
expression	NULL
have	NULL
not	NULL
been	NULL
identified	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
gene	NULL
for	NULL
the	NULL
human	NULL
HB-EGF	NULL
revealed	NULL
a	NULL
2-kilobase	NULL
DNA	NULL
fragment	NULL
that	NULL
contains	NULL
promoter	NULL
activity	NULL
and	NULL
a	NULL
potential	NULL
AP-1	NULL
site	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
this	NULL
AP-1	NULL
site	NULL
,	NULL
however	NULL
,	NULL
contains	NULL
a	NULL
single	NULL
residue	NULL
mismatch	NULL
(	NULL
7	NULL
)	NULL
that	NULL
was	NULL
found	NULL
in	NULL
a	NULL
separate	NULL
study	NULL
to	NULL
be	NULL
defective	NULL
in	NULL
binding	NULL
Fos	NULL
and	NULL
Jun	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
was	NULL
not	NULL
clear	NULL
from	NULL
the	NULL
above	NULL
study	NULL
whether	NULL
there	NULL
are	NULL
«	NULL
kB	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
HB-EGF	NULL
gene	NULL
,	NULL
results	NULL
reported	NULL
here	NULL
suggest	NULL
that	NULL
transcription	NULL
factors	NULL
with	NULL
kB	NULL
binding	NULL
capability	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
transcription	NULL
of	NULL
HB-EGF	NULL
in	NULL
monocytes	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
well	NULL
character	NULL
7790	NULL
ized	NULL
transcription	NULL
factor	NULL
whose	NULL
activity	NULL
in	NULL
non-B	NULL
lymphocytes	NULL
is	NULL
regulated	NULL
by	NULL
agents	NULL
including	NULL
those	NULL
associated	NULL
with	NULL
inflammation	NULL
and	NULL
atherogenic	NULL
lesions	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
stimulating	NULL
effect	NULL
of	NULL
several	NULL
atherogenic	NULL
factors	NULL
on	NULL
endothelial	NULL
and	NULL
smooth	NULL
muscle	NULL
cells	NULL
may	NULL
be	NULL
mediated	NULL
in	NULL
part	NULL
through	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
up-regulation	NULL
of	NULL
growth	NULL
factor	NULL
synthesis	NULL
.	NULL

PAF	NULL
has	NULL
long	NULL
been	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
atherogenesis	NULL
and	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Only	NULL
recently	NULL
,	NULL
however	NULL
,	NULL
has	NULL
evidence	NULL
begun	NULL
to	NULL
accumulate	NULL
suggesting	NULL
the	NULL
function	NULL
of	NULL
PAF	NULL
in	NULL
gene	NULL
regulation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
PAF	NULL
at	NULL
nanomolar	NULL
concentrations	NULL
is	NULL
fully	NULL
capable	NULL
of	NULL
stimulating	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
action	NULL
of	NULL
PAF	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
cell	NULL
surface	NULL
PAF	NULL
receptor	NULL
,	NULL
which	NULL
couples	NULL
to	NULL
a	NULL
G	NULL
protein	NULL
sensitive	NULL
to	NULL
pertussis	NULL
toxin	NULL
treatment	NULL
.	NULL

The	NULL
signal	NULL
transduction	NULL
mechanism	NULL
for	NULL
transcription	NULL
factor	NULL
activation	NULL
by	NULL
G	NULL
protein-coupled	NULL
receptors	NULL
remains	NULL
to	NULL
be	NULL
explored	NULL
.	NULL

Our	NULL
preliminary	NULL
results	NULL
indicate	NULL
that	NULL
PAF-mediated	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
involves	NULL
kinase	NULL
activa-tion	NULL
;	NULL
thus	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
multiple	NULL
signal	NULL
transduction	NULL
pathways	NULL
lead	NULL
to	NULL
the	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
IxB	NULL
.	NULL

Although	NULL
in	NULL
physiological	NULL
conditions	NULL
PAF	NULL
released	NULL
by	NULL
cells	NULL
is	NULL
rapidly	NULL
degraded	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
,	NULL
prolonged	NULL
exposure	NULL
of	NULL
leukocytes	NULL
to	NULL
PAF	NULL
could	NULL
be	NULL
achieved	NULL
by	NULL
the	NULL
recently	NULL
discovered	NULL
juxtacrine	NULL
intercellular	NULL
signaling	NULL
mechanism	NULL
in	NULL
which	NULL
newly	NULL
synthesized	NULL
PAF	NULL
is	NULL
presented	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
endothelial	NULL
cells	NULL
that	NULL
interact	NULL
with	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
as	NULL
well	NULL
as	NULL
residential	NULL
monocytes	NULL
and	NULL
macrophages	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
subendo-thelial	NULL
localization	NULL
of	NULL
monocyte/macrophages	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
,	NULL
sustained	NULL
high	NULL
level	NULL
synthesis	NULL
of	NULL
HB-EGF	NULL
is	NULL
possible	NULL
through	NULL
the	NULL
juxtacrine	NULL
activation	NULL
of	NULL
the	NULL
cells	NULL
tethered	NULL
by	NULL
P-selectin	NULL
and	NULL
stimulated	NULL
by	NULL
endothelial	NULL
cell	NULL
surface-associated	NULL
PAF	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
investigating	NULL
this	NULL
possibility	NULL
as	NULL
well	NULL
as	NULL
the	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
process	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Andrzej	NULL
Ptasznik	NULL
for	NULL
assistance	NULL
in	NULL
blood	NULL
cell	NULL
preparation	NULL
,	NULL
Dr.	NULL
Lili	NULL
Feng	NULL
for	NULL
helpful	NULL
discussion	NULL
,	NULL
and	NULL
Drs	NULL
.	NULL

Eric	NULL
R.	NULL
Prossnitz	NULL
and	NULL
Darren	NULL
D.	NULL
Browning	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

Note	NULL
Added	NULL
in	NULL
Proof-Two	NULL
«	NULL
B	NULL
sites	NULL
have	NULL
recently	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
mouse	NULL
gene	NULL
for	NULL
HB-EGF	NULL
(	NULL
M.	NULL
Klagsbrun	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Weyrich	NULL
et	NULL
al	NULL
.	NULL

(	NULL
37	NULL
)	NULL
found	NULL
that	NULL
interaction	NULL
of	NULL
monocytes	NULL
with	NULL
P-selectin	NULL
causes	NULL
increased	NULL
expression	NULL
of	NULL
monocyte	NULL
chemotactic	NULL
protein-1	NULL
,	NULL
TNFa	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
response	NULL
to	NULL
PAF	NULL
stimulation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ross	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
362	NULL
,	NULL
801-809	NULL
2	NULL
.	NULL

Steinberg	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Circulation	NULL
3	NULL
,	NULL
508-514	NULL
3	NULL
.	NULL

Higashiyama	NULL
,	NULL
S.	NULL
,	NULL
Abraham	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Miller	NULL
,	NULL
J.	NULL
,	NULL
Fiddes	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

PAF	NULL
Induces	NULL
HB-EGF	NULL
Gene	NULL
Expression	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
936-989	NULL
.	NULL

Dluz	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Higashiyama	NULL
,	NULL
S.	NULL
,	NULL
Damm	NULL
,	NULL
D.	NULL
,	NULL
Abraham	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
18330-18334	NULL
.	NULL

Higashiyama	NULL
,	NULL
S.	NULL
,	NULL
Abraham	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

122	NULL
,	NULL
933-940	NULL
.	NULL

Temizer	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Yoshizumi	NULL
,	NULL
M.	NULL
,	NULL
Perrella	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Susanni	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
Quertermous	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
M.-E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
24892-24896	NULL
.	NULL

Fen	NULL
,	NULL
Z.	NULL
,	NULL
Dhadly	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Yoshizumi	NULL
,	NULL
M.	NULL
,	NULL
Hilkert	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Quertermous	NULL
,	NULL
T.	NULL
,	NULL
Eddy	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Shows	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
M.-E.	NULL
(	NULL
1993	NULL
)	NULL
Biochemistry	NULL
82	NULL
,	NULL
7982-7988	NULL
.	NULL

Nakano	NULL
,	NULL
T.	NULL
,	NULL
Raines	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
Abraham	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ross	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U	NULL
.	NULL

8	NULL
.	NULL

A	NULL
.	NULL

91	NULL
,	NULL
1069-1073	NULL
.	NULL

Nakano	NULL
,	NULL
T.	NULL
,	NULL
Raines	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
Abraham	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Wenzel	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
Higashiyama	NULL
,	NULL
S.	NULL
,	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ross	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
22941-22947	NULL
Snyder	NULL
,	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

259	NULL
,	NULL
C697-C708	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Mclntyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
in	NULL
Inflammation	NULL
:	NULL
Basic	NULL
Principles	NULL
and	NULL
Clinical	NULL
Correlates	NULL
(	NULL
Gallin	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
Gold-stein	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
and	NULL
Snyderman	NULL
,	NULL
R.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

149-176	NULL
,	NULL
Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
Hwang	NULL
,	NULL
S.	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Lipid	NULL
Mediators	NULL
2	NULL
,	NULL
123-158	NULL
Chao	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Olson	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

2902	NULL
,	NULL
617-629	NULL
Honda	NULL
,	NULL
Z.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Miki	NULL
,	NULL
L	NULL
,	NULL
Minami	NULL
,	NULL
M.	NULL
,	NULL
Watanabi	NULL
,	NULL
T.	NULL
,	NULL
Seyama	NULL
,	NULL
Y.	NULL
,	NULL
Okado	NULL
,	NULL
H.	NULL
,	NULL
Toh	NULL
,	NULL
H.	NULL
,	NULL
Ito	NULL
,	NULL
K.	NULL
,	NULL
Miyamoto	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Shimizu	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
849	NULL
,	NULL
342-345	NULL
Ye	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Prossnitz	NULL
,	NULL
A	NULL
.	NULL

Z.	NULL
,	NULL
Zou	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Cochrane	NULL
,	NULL
C.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

180	NULL
,	NULL
105-111	NULL
Nakamura	NULL
,	NULL
M.	NULL
,	NULL
Honda	NULL
,	NULL
Z.	NULL
,	NULL
Izumi	NULL
,	NULL
T.	NULL
,	NULL
Sakanaka	NULL
,	NULL
C.	NULL
,	NULL
Mutoh	NULL
,	NULL
H.	NULL
,	NULL
Minami	NULL
,	NULL
M.	NULL
,	NULL
Bito	NULL
,	NULL
H.	NULL
,	NULL
Seyama	NULL
,	NULL
Y.	NULL
,	NULL
Matsumoto	NULL
,	NULL
T.	NULL
,	NULL
Noma	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Shimizu	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
20400-20405	NULL
Kunz	NULL
,	NULL
D.	NULL
,	NULL
Gerard	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
and	NULL
Gerard	NULL
,	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
9101-9106	NULL
Bourgain	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Maes	NULL
,	NULL
C.	NULL
,	NULL
Braquet	NULL
,	NULL
P.	NULL
,	NULL
Andires	NULL
,	NULL
R.	NULL
,	NULL
Torqui	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Braquet	NULL
,	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Prostaglandins	NULL
30	NULL
,	NULL
185-197	NULL
Koltai	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Braquet	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Agents	NULL
Actions	NULL
87	NULL
,	NULL
333-339	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Melntyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
93-100	NULL
Chomczynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
(	NULL
abstr	NULL
.	NULL
)	NULL

Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
Vogelstein	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

182	NULL
,	NULL
6-13	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
Hwang	NULL
,	NULL
S.-B	NULL
.	NULL

,	NULL
and	NULL
Lam	NULL
,	NULL
M.-H.	NULL
(	NULL
1991	NULL
)	NULL
Lipids	NULL
26	NULL
,	NULL
1148-1153	NULL
Casals-Stenzel	NULL
,	NULL
J.	NULL
,	NULL
Muacevic	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Weber	NULL
,	NULL
K.-H.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

241	NULL
,	NULL
974-981	NULL
Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
Schreck	NULL
,	NULL
R.	NULL
,	NULL
Meier	NULL
,	NULL
B.	NULL
,	NULL
Mannel	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
Drige	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1181-1194	NULL
Besner	NULL
,	NULL
G.	NULL
,	NULL
Higashiyama	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Klagsbrun	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
Regul	NULL
.	NULL

1	NULL
,	NULL
811-819	NULL
Yoshizumi	NULL
,	NULL
M.	NULL
,	NULL
Kourembanas	NULL
,	NULL
S.	NULL
,	NULL
Temizer	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Cambria	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Quertermous	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
M.-E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
9467-9469	NULL
Risse	NULL
,	NULL
G.	NULL
,	NULL
Jooss	NULL
,	NULL
K.	NULL
,	NULL
Neuberg	NULL
,	NULL
M.	NULL
,	NULL
Bruller	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
and	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
3825-3832	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

82	NULL
,	NULL
141-179	NULL
Tripathi	NULL
,	NULL
Y	NULL
.	NULL

B.	NULL
,	NULL
Lim	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Ferandez-Galllardo	NULL
,	NULL
S.	NULL
,	NULL
Kandala	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Guntaka	NULL
,	NULL
R.	NULL
V.	NULL
,	NULL
and	NULL
Shukla	NULL
,	NULL
S.	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

286	NULL
,	NULL
527-533	NULL
Blank	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Lee	NULL
,	NULL
T.	NULL
,	NULL
Fitzgerald	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Snyder	NULL
,	NULL
F.	NULL
(	NULL
1981	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

256	NULL
,	NULL
175-178	NULL
Stafforini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
4223-4230	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Mcintyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Mehra	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

110	NULL
,	NULL
529-540	NULL
Lorant	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Patel	NULL
,	NULL
K.	NULL
D.	NULL
,	NULL
Mclntyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
McEver	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

115	NULL
,	NULL
223-234	NULL
Weyrich	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
McIntyre	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
McEver	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Prescott	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Zimmerman	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
in	NULL
press	NULL

